Termination of early pregnancy. Future development.
D015064:16,16-Dimethylprostaglandin E2 / Q000009:adverse effects / Q000031:analogs & derivatives; D000020:Abortifacient Agents, Nonsteroidal; D000028:Abortion, Induced / Q000379:methods*; D015232:Dinoprostone / Q000031:analogs & derivatives*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D010146:Pain; D011247:Pregnancy; D011459:Prostaglandins E, Synthetic / Q000008:administration & dosage / Q000009:adverse effects; D012646:Self Administration; D013488:Suppositories; D014621:Vagina
D000020:Abortifacient Agents, Nonsteroidal; D011459:Prostaglandins E, Synthetic; D013488:Suppositories; C025505:meteneprost; C017244:16,16-dimethylprostaglandin E; C016767:sulprostone; D015232:Dinoprostone; D015064:16,16-Dimethylprostaglandin E2